ReviewTherapeutics and clinical risk management2026
Adjunctive Cannabidiol for Drug-Resistant Epilepsy: A Systematic Review and Meta-Analysis of Randomized Trials Across Syndromes, Formulations, and Dose Ranges.
Review in Therapeutics and clinical risk management, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cannabidiol (CBD) has emerged as a promising adjunctive therapy for drug-resistant epilepsy, yet clinical findings remain heterogeneous across trials. This meta-analysis aimed to evaluate the efficacy, safety, and formulation-dependent performance of CBD in patients with treatment-resistant epilepsies. Methods: A systematic review and meta-analysis were conducted in accordance with PRISMA 2020 guidelines, including randomized, double-blind, placebo-controlled trials of adjunctive CBD in drug-resistant epilepsy. Literature was sourced from PubMed/MEDLINE, Scopus, and the Cochrane Central Register of Controlled Trials (CENTRAL). Data were synthesized using random-effects models to estimate pooled risk ratios (RRs) with 95% confidence intervals (CIs) for seizure reduction and adverse events. Subgroup analyses explored the influence of epilepsy syndrome, CBD dose, and formulation type. Results: Seven randomized controlled trials involving 1154 participants met inclusion criteria. Adjunctive CBD significantly reduced seizure frequency compared with placebo (pooled RR = 0.72, 95% CI 0.71-0.73; p < 0.0001). The effect was consistent across Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex, with optimal efficacy observed at 20 mg/kg per day of highly purified oral CBD. Liposomal CBD produced modest benefit, whereas transdermal formulations showed no short-term efficacy. Adverse events were predominantly mild and comparable to placebo, although elevations in hepatic enzymes and somnolence occurred more frequently in patients receiving concomitant valproate or clobazam. Conclusion: Adjunctive oral CBD provides a reproducible and clinically meaningful reduction in seizures in drug-resistant epilepsy, with an acceptable safety profile. Oral CBD at 20 mg/kg per day represents the current benchmark for efficacy, while alternative formulations require further evaluation. Future research should address long-term outcomes, optimal dosing strategies, and formulation refinement to improve tolerability and accessibility in diverse epileptic populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.